



Sp1 is targeted by miR-145-5p in non-small cell lung cancer cells and participates BMI1 induced pemetrexed resistance and epithelial-mesenchymal transition

Wen-Wei Chang ^{1,2*}, Bing-Yen Wang ^{3,4*}, Shih-Hong Chen ¹, Peng-Ju Chien ¹, Gwo-Tarn Sheu ⁵ and Ching-Hsiung Lin ^{6,7,8,9*}




Figure S1. Survival analysis of BMI1, SP1, or ZEB1 in NSCLC patients. Survival analysis based on single gene of BMI1, SP1, or ZEB1 in NSCLC subjects of TCGA database was analyzed using GEPIA2 webtools using median expression level as the cut-off. The statistical analysis was performed by a log rank test.

Table S1. The information of antibodies used in this study.

<i>Product</i>	<i>Source</i>	<i>Catalogue No.</i>
Primary antibody:		
anti-BMI1	Cell Signaling Technology, Inc.	6964s
anti-E-Cadherin	Santa Cruz Biotechnology, Inc	sc-21791
anti-N-Cadherin	Santa Cruz Biotechnology, Inc	sc-59987
anti-SNAI1	Cell Signaling Technology, Inc.	3879s
anti-ZEB1	GeneTex International Corporation	GTX105278
anti-GAPDH	GeneTex International Corporation	GTX100118
Anti- β -actin	Sigma-Aldrich	A5441
Secondary antibodies:		
anti-rabbit IgG-HRP	GeneTex International Corporation	GTX221666-01
anti-mouse IgG-HRP	GeneTex International Corporation	GTX221667-01

Table S2. Primer Sequences for the construction of Sp1 3'-UTR reporter vectors.

<i>Primer name</i>	<i>Sequences (5' to 3')</i>
WT-F-EcoRI	GAATTCTGTGGGATAAAGATTATGATTAGGG
WT-R-XbaI	TCTAGAGCTGCGACCTTTCTTTCATC
Mut-F	AGCTGCAGATCTTTGCTAG
Mut-R	ACAATGTGAAGATATTAACAATACAAAATATATTTTG